A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

Trial Profile

A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2017

At a glance

  • Drugs E 6011 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors EA Pharma; Eisai Co Ltd
  • Most Recent Events

    • 10 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Feb 2017 Planned number of patients changed from 24 to 21.
    • 23 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top